Instituto de Oncología Angel H. Roffo ( Site 0503)

Buenos Aires, Buenos Aires F.D. C1417

1 studies enrolling now · 1 studies all time

What they study most

Triple-Negative Breast Cancer

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) — Recruiting now